• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > About > Annual reports
2024
ANNUAL REPORT
SOLIDARITY IN SCIENCE
2024 ANNUAL REPORT
2024 FINANCIAL REPORT
  • FOREWORD
  • HIGHLIGHTS
  • 2024 IN NUMBERS
  • DNDi WORLDWIDE
  • OUR PROGRESS
  • R&D PORTFOLIO
  • PARTNERS
  • PERFORMANCE
  • THANKS

Medical innovation should serve everyone, everywhere. Our founding motto, ‘Best Science for the Most Neglected’, remains our calling.

Foreword

2024 will be remembered as a year of geopolitical turbulence that also saw the beginnings of drastic cuts to global health programmes and assaults on international health cooperation.

We stand firmly with our allies working to resist these alarming threats and stand ready to work with countries confronting urgent new challenges with bolstered leadership and conviction.

READ MORE
Highlights
Bringing elimination within reach
DISCOVER
Highlights
Pushing to end the double neglect
DISCOVER
Highlights
Confronting the climate crisis
DISCOVER
Highlights
Shaping a fairer response to future pandemics
DISCOVER
Highlights
Putting patients at the centre – start to finish
DISCOVER

2024 in numbers

32
projects

in our R&D portfolio, and an additional 14 projects in the treatment access phase

16
clinical trials

in 7 disease areas, including 10 trials testing new chemical entities

4,214
patients

enrolled in active DNDi clinical studies

3:1
ratio

of partner staff vs DNDi staff* worldwide

*Staff in full-time equivalents (FTEs)

29
nationalities

represented among DNDi employees on 5 continents

DISCOVER

DNDi WORLDWIDE

Sleeping sickness
Francis
Gome Village, Ntchisi, Malawi
“I am feeling fine now that I am completely cured, and I’m looking forward to going back to my normal life as a farmer and taking care of my family.”
Learn about our progress
Leishmaniasis
Nand
Balwan Tola, Bihar, India
“This disease took away my will to live.”
Learn about our progress
Leishmaniasis
Abdella
Southern Ethiopia
“People keep asking me what happened to my face and why the scar is not going away. I don’t have an answer for them.”
Learn about our progress
Chagas disease
Maria Eusebia
Machin, Sierra Nevada de Santa Marta mountains, Colombia
“They tell me that they no longer feel the tiredness they felt before. That makes me feel very good.”
Learn about our progress
Parasitic worms
‘Mama Cecile’
Babagulu, Democratic Republic of the Congo
“One day I went to tend to the fields. I was walking behind one of my children and then I started to see poorly – I almost fell into a hole.”
Learn about our progress
Mycetoma
Jennifer
Turkana County, Kenya
“I am hopeful that someday I will be free from this disease and get a chance to go back to school.”
Learn about our progress
Dengue
Jacira
Morro dos Prazeres, Rio de Janeiro, Brazil
“It’s not fair – children are dying, teenagers are dying, adults are dying. I’d really like something to prevent these deaths.”
Learn about our progress
HIV
Dr Cecilia Kanyama
Kamuzu Central Hospital, Malawi
“If successful, this new formulation will be a game-changer. It will simplify treatment for both patients and healthcare providers.”
Learn about our progress
Hepatitis C
Sharol
Kedah, Malaysia
“This medicine had no side effects on me at all. It made me happy because it did not disrupt my daily routine at all. Everything is okay now and I am cured.”
Learn about our progress

DNDi WORLDWIDE

Clinical sites

  • Sleeping sickness
  • Leishmaniasis
  • Chagas disease
  • Parasitic worms
  • Mycetoma
  • HIV
  • Pandemic preparedness
  • R&D AND ACCESS PARTNERS
  • DNDi OFFICES
  • FOUNDING PARTNERS
  • COUNTRIES WITH DNDi ACTIVITIES

OUR PROGRESS

SLEEPING SICKNESS
LEISHMANIASIS
CHAGAS DISEASE
PARASITIC WORMS
MYCETOMA
DENGUE
HIV
HEPATITIS C

RESEARCH & DEVELOPMENT PORTFOLIO

RESEARCH & DEVELOPMENT PORTFOLIO

Acting as a ‘conductor of a virtual orchestra’, we collaborate with research partners around the world at all stages of the R&D process.

Our R&D portfolio includes nine disease areas and 46 projects, 21 of which are focused on identifying or developing new chemical entities.

EXPLORE PORTFOLIO

Partners

DNDi’s worldwide footprint is anchored 
in endemic countries​ 

FIND OUT MORE

Performance

88% of 2024 DNDi expenditure was for our social mission across R&D and access, Capacity strengthening, Policy, and Advocacy & Communication

FIND OUT MORE

A WORD OF THANKS

DNDi has delivered 13 new treatments for six neglected diseases since 2003. We are deeply grateful to our partners and donors for their collaboration and support.

OUR PARTNERS
OUR DONORS

Photo credits: Lameck Ododo-DNDi; Brent Stirton/Getty Images; Neil Brandvold-DNDi; Xavier Vahed-DNDi; WHO/Violaine Martin; Felipe Abondano-DNDi; Thoko Chikondi-DNDi; Aliya Bashir/DNDi; Ley Uwera-DNDi; Fábio Nascimento-DNDi; FARMOVS/Vicky Simpson-DNDi; Abang Amirrul Hadi-DNDi

Stay connected

Get our latest news, personal stories, research articles, and job opportunities.

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License